Breaking News Instant updates and real-time market news.

VRX

Valeant

$17.00

-0.1598 (-0.93%)

, TKPYY

Takeda Pharmaceutical Co. Ltd.

$20.97

-0.035 (-0.17%)

10:01
11/30/16
11/30
10:01
11/30/16
10:01

Valeant talks to sell Salix to Takeda for about $10B break down, DJ reports

VRX

Valeant

$17.00

-0.1598 (-0.93%)

TKPYY

Takeda Pharmaceutical Co. Ltd.

$20.97

-0.035 (-0.17%)

  • 13

    Dec

  • 14

    Dec

  • 16

    Feb

VRX Valeant
$17.00

-0.1598 (-0.93%)

11/18/16
DBAB
11/18/16
NO CHANGE
Target $24
DBAB
Hold
Deutsche still likes near-term setup for Valeant shares
Deutsche Bank analyst Gregg Gilbert said yesterday that he still likes the near-term setup for shares of Valeant Pharmaceuticals after federal prosecutors announced criminal charges against former executive Gary Tanner and the former CEO of Philidor. It is "good to see" that Valeant and other senior executives were not charged, Gilbert told investors in a research note. The charges could be an important step forward as the company and new management team distance themselves from the past, Gilbert wrote. The analyst points out that the bar for 2016 has already been lowered and that new CFO Paul Herendeen thinks of guidance as a commitment. Gilbert keeps a Hold rating on Valeant with a $24 price target. The stock closed yesterday up 12c to $17.98.
11/18/16
ADAM
11/18/16
NO CHANGE
Target $17
ADAM
Hold
Valeant negative headlines remain a risk, says Canaccord
Canaccord analyst Neil Maruoka noted yesterday's headlines regarding criminal charges against a former Valeant executive. He said although the charges are not pertinent to Valeant it underscores the negative headline risk that is associated with owning the shares. Maruoka said the company's lower guidance suggests growth headwinds into next year and believes the company still needs to sell assets to de-lever. Maruoka maintained his Hold rating and $17 price target on Valeant shares.
11/23/16
MZHO
11/23/16
DOWNGRADE
Target $11
MZHO
Underperform
Valeant downgraded to Underperform from Neutral at Mizuho
Mizuho analyst Irina Koffler downgraded Valeant Pharmaceuticals to Underperform, her firm's sell rating equivalent, and cut her price target for the shares to $11 from $25. The drugmaker closed yesterday at $17.83. Koffler believes growth challenges, 2017 guidance risk, legal overhangs and weaker asset divestitures create an unfavorable risk/reward profile. She expects the shares to trend lower over the next 6-12 months.
11/29/16
DBAB
11/29/16
NO CHANGE
Target $24
DBAB
Hold
Deutsche weighs impact on Valeant should Salix be sold
Deutsche Bank analyst Gregg Gilbert hopes to hear closure soon on a potential sale of Salix by Valeant Pharmaceuticals. While a sale is not a "no-brainer" given the unit's growth and durability, a deal could improve Valeant's debt situation and add to its value, Gilbert tells investors in a research note. His preliminary analysis suggests that a sale of Salix for $10B coupled with de-levering would be "significantly" dilutive to earnings but accretive to Valeant's value. His analysis yields earnings dilution of 26%-27% in 2018- 2021 and an increase in the company's theoretical discounted cash flow value to $32 from $24. Gilbert continues to like the near-term setup in shares of Valeant but keeps a Hold rating on the shares with a $24 price target. The pharmaceutical closed yesterday up 44c to $17.44.
TKPYY Takeda Pharmaceutical Co. Ltd.
$20.97

-0.035 (-0.17%)

06/08/16
RHCO
06/08/16
NO CHANGE
RHCO
Ultragenyx collaboration with Takeda 'exceptionally positive,' says SunTrust
After Ultragenyx (RARE) announced a development and commercialization collaboration for rare genetic diseases with Takeda (TKPYY), SunTrust says the deal terms are "exceptionally positive" for Ultragenyx. The firm notes that the latter company will receive both compounds and cash payments from Takeda, while Takeda will only get comemrcial rights in Asia. The firm keeps a Buy rating on Ultragenyx.
07/07/16
UBSW
07/07/16
INITIATION
UBSW
Neutral
Takeda Pharmaceutical initiated with a Neutral at UBS
UBS analyst Atsushi Seki started Takeda with a Neutral rating and Y4,600 price target.
09/14/16
SBSH
09/14/16
NO CHANGE
Target $4
SBSH
Neutral
Citi views Synergy Pharmaceuticals as potential target for Takeda
Citi analyst Liav Abraham calls Synergy Pharmaceuticals (SGYP) the most likely potential target for Takeda Pharmaceutical (TKPYY) among her coverage universe. The Financial Times earlier today reported that Takeda is ready to spend as much as $15B in acquisitions to expand its business in the United States. Abraham has a Neutral rating on Synergy with a $4 price target. The analyst sees Synergy as a potential target given the "extensive resources" needed to commercialize its lead asset, plecanatide, as well as Takdea's presence in the irritable bowel syndrome/chronic idiopathic constipation space. Shares of Synergy are up 6% to $5.18 in early trading.
09/15/16
WELS
09/15/16
NO CHANGE
WELS
Street underestimating potential of PRA Health deal, says Wells Fargo
Wells Fargo believes that the Street is underestimating the potential benefit to PRA Health (PRAH) of its deal with Takeda (TKPYY). The firm expects PRA's bookings over the next year to significantly exceed the industry average, causing 2017 and 2018 consensus estimates for the company to rise. Wells raised its price target on PRA to $65-$67 from $56-$59 and keeps an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

AAPL

Apple

$109.95

0.84 (0.77%)

, GOOG

Alphabet

$759.11

-3.41 (-0.45%)

09:21
12/07/16
12/07
09:21
12/07/16
09:21
Hot Stocks
Kantar says Apple iOS share gains driven by iPhone 7 sales »

Kantar Worldpanel ComTech…

AAPL

Apple

$109.95

0.84 (0.77%)

GOOG

Alphabet

$759.11

-3.41 (-0.45%)

GOOGL

Alphabet Class A

$776.18

-2.04 (-0.26%)

MSFT

Microsoft

$59.95

-0.27 (-0.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jan

  • 13

    Mar

AZO

AutoZone

09:20
12/07/16
12/07
09:20
12/07/16
09:20
Recommendations
AutoZone analyst commentary  »

AutoZone price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

AAPL

Apple

$109.95

0.84 (0.77%)

09:18
12/07/16
12/07
09:18
12/07/16
09:18
Downgrade
Apple rating change  »

Apple downgraded to Mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

SBUX

Starbucks

$57.44

-0.06 (-0.10%)

09:18
12/07/16
12/07
09:18
12/07/16
09:18
Hot Stocks
Starbucks says five-year goal is to 'elevate the brand' »

Also says goal is to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

NBR

Nabors Industries

09:16
12/07/16
12/07
09:16
12/07/16
09:16
Downgrade
Nabors Industries rating change  »

Nabors Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FIT

Fitbit

09:16
12/07/16
12/07
09:16
12/07/16
09:16
Hot Stocks
Fitbit acquires certain assets from Pebble, deal excludes hardware products »

Fitbit announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

AVAV

AeroVironment

$29.34

0.76 (2.66%)

09:15
12/07/16
12/07
09:15
12/07/16
09:15
Hot Stocks
AeroVironment, Cal State Fresno to research water stress in almond trees »

AeroVironment announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:15
12/07/16
12/07
09:15
12/07/16
09:15
General news
Energy Action: NYMEX crude »

Energy Action: NYMEX…

CLB

Core Laboratories

09:13
12/07/16
12/07
09:13
12/07/16
09:13
Downgrade
Core Laboratories rating change  »

Core Laboratories…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

ETFC

E-Trade

$35.52

0.31 (0.88%)

09:11
12/07/16
12/07
09:11
12/07/16
09:11
Hot Stocks
E-Trade CEO says running to grow company, not sell it »

Says running a company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

SBUX

Starbucks

$57.44

-0.06 (-0.10%)

09:09
12/07/16
12/07
09:09
12/07/16
09:09
Hot Stocks
Breaking Hot Stocks news story on Starbucks »

Starbucks says sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

S

Sprint

$8.17

0.12 (1.49%)

09:08
12/07/16
12/07
09:08
12/07/16
09:08
Hot Stocks
Sprint becomes first U.S. Pokemon GO partner »

Sprint and Niantic,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 04

    Jan

RES

RPC, Inc.

$21.39

-0.24 (-1.11%)

09:08
12/07/16
12/07
09:08
12/07/16
09:08
Downgrade
RPC, Inc. rating change  »

RPC, Inc. downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:07
12/07/16
12/07
09:07
12/07/16
09:07
Conference/Events
Cowen analysts hold an analyst/industry conference call »

Analysts hold an…

HBAN

Huntington Bancshares

$13.22

0.19 (1.46%)

09:07
12/07/16
12/07
09:07
12/07/16
09:07
Hot Stocks
Huntington Bancshares sees FY17 revenue growth of 20%+ »

Says implementation of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

OCRX

Ocera Therapeutics

$2.35

0.1 (4.44%)

09:05
12/07/16
12/07
09:05
12/07/16
09:05
Hot Stocks
Ocera Therapeutics completes enrollment in STOP-HE Phase 2b study »

Ocera Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIGM

Sigma Designs

$7.75

0.1 (1.31%)

09:05
12/07/16
12/07
09:05
12/07/16
09:05
Downgrade
Sigma Designs rating change  »

Sigma Designs downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

SLM

Sallie Mae

$10.78

0.23 (2.18%)

09:05
12/07/16
12/07
09:05
12/07/16
09:05
Recommendations
Sallie Mae analyst commentary  »

Sallie Mae price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RGC

Regal Entertainment

$22.13

0.17 (0.77%)

09:05
12/07/16
12/07
09:05
12/07/16
09:05
Hot Stocks
Regal Entertainment partners with myLINGO for non-English movie audio »

Regal Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

SBUX

Starbucks

$57.44

-0.06 (-0.10%)

09:05
12/07/16
12/07
09:05
12/07/16
09:05
Hot Stocks
Starbucks says plans to introduce standalone Princi bakery stores »

Will open standalone…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

09:04
12/07/16
12/07
09:04
12/07/16
09:04
Conference/Events
SunTrust to hold a field trip »

Bank Field Trip travels…

MDT

Medtronic

$72.11

0.44 (0.61%)

, FIT

Fitbit

$7.98

-0.05 (-0.62%)

09:04
12/07/16
12/07
09:04
12/07/16
09:04
Hot Stocks
Medtronic enters partnership with Fitbit »

Medtronic (MDT) and…

MDT

Medtronic

$72.11

0.44 (0.61%)

FIT

Fitbit

$7.98

-0.05 (-0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 12

    Dec

BPMX

BioPharmX

$0.43

0.0029 (0.67%)

09:03
12/07/16
12/07
09:03
12/07/16
09:03
Hot Stocks
BioPharmX's BPX-01 gel shows potential reduction of acne-associated inflammation »

BioPharmX will share…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UPS

UPS

$116.54

-0.02 (-0.02%)

09:03
12/07/16
12/07
09:03
12/07/16
09:03
Hot Stocks
UPS announces first U.S. delivery eBile debuts in Portland, OR »

UPS announced its first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$266.00

-0.93 (-0.35%)

09:03
12/07/16
12/07
09:03
12/07/16
09:03
Hot Stocks
Sikorsky signs contract with Chilean Air Force for six S-70i Black Hawks »

Sikorsky, a Lockheed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.